Dulbecco Pietro, Gambaro Camilla, Bilardi Claudio, Zentilin Patrizia, Mele Maria Raffaella, Mansi Carlo, Biagini Riccardo, Tessieri Laura, Iiritano Elena, Usai Paolo, Vigneri Sergio, Savarino Vincenzo
Dipartimento di Medicina Interna e Specialità Mediche, Università di Genova, Italy.
Dig Dis Sci. 2003 Feb;48(2):315-21. doi: 10.1023/a:1021931627698.
No previous study has analyzed the impact of long-term antisecretory drugs on the precision of [13C]urea breath test (UBT). We assessed the rate of UBT conversion from positive to negative results during 60-day therapy with standard doses of ranitidine and pantoprazole. For this purpose, we recruited 60 dyspeptic patients with H. pylori infection ascertained on the basis of the concomitant results of CLO-test, histology, and UBT. Our patients were randomly assigned to receive ranitidine 300 mg at night or pantoprazole 40 mg in the morning for 60 days. UBT was performed at baseline and on days 14, 30, and 60, while patients were still taking antisecretory drugs. Patients with false-negative UBT on day 60 repeated the test every 3 days until conversion. After overnight fasting, duplicate breath test samples were taken from each patient before and 30 min after ingestion of 75 mg [13C]urea dissolved in 150 ml of 0.033 mol/liter citric acid. Four patients dropped out of the study. Both drugs induced similar false-negative UBTs on day 14 of dosing (P = 0.5). Afterwards, the three false-negative UBTs in the ranitidine group again became positive during therapy and particularly on day 30 of dosing. Of the four false-negative UBTs in the pantoprazole group at day 60, one became positive after 3 and three after 9 days of therapy cessation. Our findings show that the long-term use of ranitidine and pantoprazole at standard doses has different effects on the results of UBT. In the pantoprazole group patients again became positive within 3-9 days after stopping 60-day therapy, whereas in the ranitidine group patients reverted to positive on day 30 of dosing while they were still on treatment and this was likely due to development of tolerance. Therefore, patients taking pantoprazole need at least a 10-day withdrawal before UBT testing, while those taking ranitidine for at least 30 days can undergo UBT without the necessity of a wash-out period.
既往尚无研究分析长期使用抗分泌药物对[13C]尿素呼气试验(UBT)准确性的影响。我们评估了在使用标准剂量雷尼替丁和泮托拉唑进行60天治疗期间UBT从阳性转为阴性结果的比率。为此,我们招募了60名消化不良患者,根据CLO试验、组织学和UBT的联合结果确定其感染幽门螺杆菌。我们的患者被随机分配接受每晚300mg雷尼替丁或每日晨服40mg泮托拉唑,持续60天。在基线以及第14、30和60天进行UBT检测,此时患者仍在服用抗分泌药物。第60天UBT结果为假阴性的患者每3天重复检测一次,直至结果转为阳性。在隔夜禁食后,在每位患者摄入溶解于150ml 0.033mol/L柠檬酸中的75mg[13C]尿素之前及之后30分钟采集两份呼气试验样本。4名患者退出研究。两种药物在给药第14天时诱导产生的假阴性UBT相似(P = 0.5)。之后,雷尼替丁组的3例假阴性UBT在治疗期间再次转为阳性,尤其是在给药第30天时。在泮托拉唑组第60天的4例假阴性UBT中,1例在停药3天后转为阳性,3例在停药9天后转为阳性。我们的研究结果表明,长期使用标准剂量的雷尼替丁和泮托拉唑对UBT结果有不同影响。在泮托拉唑组,患者在60天治疗停止后3 - 9天内再次转为阳性,而在雷尼替丁组,患者在给药第30天仍在治疗时就恢复为阳性,这可能是由于耐受性的产生。因此,服用泮托拉唑的患者在进行UBT检测前至少需要停药10天,而服用雷尼替丁至少30天的患者可以进行UBT检测,无需洗脱期。